ACRSAclaris Therapeutics, Inc.

ACRS Stock Price, Valuation & Chart | Aclaris Therapeutics, Inc.

Compare

$6.180+0.16 (+2.66%)

At close · 02 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Medical - Diagnostics & Research ACRS intrinsic value ACRS calculated fair value vs price

Overview Financials Dividends Ratios

ACRS Historical price chart

ACRS Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization863.12M

PE Ratio-10.66

EPS-0.58

Trading Volume1.55M

Today's High/Low6.25/5.87

Dividend Yield0.00

52 Week High/Low6.6/1.74

Shares Outstanding139.66M

ACRS Financial Statement

ACRS Analyst ratings

ACRS Analysis & performance metrics

ACRS Company profile

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It…

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory…

ACRS Management team

Name

Position

Jon Jacobsen Ph.D.

Senior Vice President of Chemistry

Matthew Rothman J.D.

General Counsel & Corporate Secretary

Steve Tucker

Executive Vice President of Project Leadership

Joseph Monahan Ph.D.

Chief Scientific Officer

William C. Roberts

Senior Vice President of Corporate Communications & Investor Relations

James Loerop

Chief Business Officer

Ajay Aggarwal M.B.A., M.D.

Senior Vice President of Clinical Development

Hugh M. Davis Ph.D.COO

President, Chief Operating Officer & Director

Name

Position

Jon Jacobsen Ph.D.

Senior Vice President of Chemistry

Matthew Rothman J.D.

General Counsel & Corporate Secretary

Steve Tucker

Executive Vice President of Project Leadership

Joseph Monahan Ph.D.

Chief Scientific Officer

William C. Roberts

Senior Vice President of Corporate Communications & Investor Relations

James Loerop

Chief Business Officer

Ajay Aggarwal M.B.A., M.D.

Senior Vice President of Clinical Development

Hugh M. Davis Ph.D.COO

President, Chief Operating Officer & Director

Management Team

Jon Jacobsen Ph.D.

Senior Vice President of Chemistry

Matthew Rothman J.D.

General Counsel & Corporate Secretary

Steve Tucker

Executive Vice President of Project Leadership

Joseph Monahan Ph.D.

Chief Scientific Officer

William C. Roberts

Senior Vice President of Corporate Communications & Investor Relations

James Loerop

Chief Business Officer

Ajay Aggarwal M.B.A., M.D.

Senior Vice President of Clinical Development

Hugh M. Davis Ph.D.COO

President, Chief Operating Officer & Director

Management

Jon Jacobsen Ph.D.

Senior Vice President of Chemistry

Matthew Rothman J.D.

General Counsel & Corporate Secretary

Steve Tucker

Executive Vice President of Project Leadership

Joseph Monahan Ph.D.

Chief Scientific Officer

William C. Roberts

Senior Vice President of Corporate Communications & Investor Relations

James Loerop

Chief Business Officer

Ajay Aggarwal M.B.A., M.D.

Senior Vice President of Clinical Development

Hugh M. Davis Ph.D.COO

President, Chief Operating Officer & Director

Total 8 executives

ACRS Frequently asked questions

What is Aclaris Therapeutics, Inc. (ACRS) Stock Price?

Current stock price of Aclaris Therapeutics, Inc. (ACRS) stock is $6.180. The stock price is +2.66% higher in the session. The intraday range can be seen from this page. Volume of Aclaris Therapeutics, Inc. (ACRS) stock is 1.55M.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the Aclaris Therapeutics, Inc. (ACRS) stock price going up or down today?

The stock price of Aclaris Therapeutics, Inc. (ACRS) can change with earnings, company news, and overall market sentiment. Aclaris Therapeutics, Inc. operates in the Healthcare / Medical - Diagnostics & Research market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Aclaris Therapeutics, Inc. stock expensive at its current price?

Whether Aclaris Therapeutics, Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for ACRS on this page is -10.66. EPS on this page is -0.58. Compare those figures with peers and growth expectations before deciding if the current Aclaris Therapeutics, Inc. price is justified.

How has the stock price of Aclaris Therapeutics, Inc. (ACRS) performed historically?

Historical performance for Aclaris Therapeutics, Inc. (ACRS) is shown on the price chart on this page. Review multi-period moves alongside volume to see how ACRS reacted to past earnings and market events.

Should I buy Aclaris Therapeutics, Inc. (ACRS) stock, at this price?

Buying Aclaris Therapeutics, Inc. (ACRS) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.